Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 5NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Methotrexate 10Cyclophosphamide 10Cytarabine 9merphos 7Vincristine 7Asparaginase 7Specimen Handling 6Methylprednisolone 6Hydrocortisone 6Daunorubicin 6pegaspargase 5fludarabine phosphate 5Prednisone 5Mercaptopurine 5fludarabine 4calaspargase pegol 4Whole-Body Irradiation 4Prednisolone 4Mycophenolic Acid 4Leucovorin 4Filgrastim 4Dexamethasone 4Busulfan 4Biopsy 4prednylidene 3dexamethasone acetate 3dexamethasone 21-phosphate 3deltacortene 3azathiopurine 3auricularum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Biphenotypic, Acute × blinatumomab × Clear all
NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡